Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO Trial

S. L. Hauser, J. S. Wolinsky, B. Brochet, X. Montalban, R. T. Naismith, M. Manfrini, M. Garas, P. Villoslada, F. Model, S. Hubeaux, L. Kappos